Importantly, oncogenic KRAS signaling was a strong driver of the COX2/PGE2 signaling axis in both mouse and human lung adenocarcinoma, and COX2 inhibition delayed tumor relapse after KRASG12C inhibition. Here, KRAS is linked to lung adenocarcinoma.